menu
    • menu
    [{"orgOrder":0,"company":"Orgenesis","sponsor":"Williamsburg Venture Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"ORGCAR19","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Williamsburg Venture Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Williamsburg Venture Holdings"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Orgenesis \/ Leidos"}]

    Find Clinical Drug Pipeline Developments & Deals by Orgenesis

    Menu

    Orgenesis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orgenesis

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORGCAR19

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Williamsburg Venture Holdings

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Orgenesis Secures up to $5 Million Equity Investment from Williamsburg Venture Holdings

                            Details : The financing will be used for the development of company's pipeline, including ORGCAR19, a chimeric antigen receptor T-cell (CAR-T) therapy used to treat B-cell acute lymphoblastic leukemia.

                            Product Name : ORGCAR19

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 28, 2025

                            Lead Product(s) : ORGCAR19

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Williamsburg Venture Holdings

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orgenesis

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Leidos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19

                            Details : Orgenesis has entered into a preliminary, non-binding term sheet with Leidos to develop and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the systemic treatment of patients suffering with SARS-CoV-2 the virus that causes COVID-...

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Leidos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth